Immix Biopharma, Inc.
Agent51Agent Readiness: 51/100. Top 25%. Measured by StartupHub.ai. Median 41.Trust82Data Trust: 82/100. Top 25%. Measured by StartupHub.ai. Median 61.A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.
About
Immix Biopharma is a biopharmaceutical company developing a revolutionary one-time CAR-T therapy, NXC-201, designed to re-engineer the immune system to fight AL Amyloidosis. This therapy targets diseased cells, aiming to normalize disease within days and provide a durable response with minimal side effects, particularly for vulnerable patients with heart involvement. Immix Biopharma is focused on creating medicines that are both effective and safe, addressing the critical unmet need for relapsed/refractory AL amyloidosis patients.
Similar companies
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Pharmaceuticals
Biotechnology company developing and commercializing cell therapies for cancer treatment.
Shares Biotechnology, Pharmaceuticals
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Pharmaceuticals
Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
Shares Biotechnology, Rare Diseases
A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.
Shares Biotechnology, Genomics
Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
Shares Biotechnology, Pharmaceuticals
Key facts
- Website
- immixbio.com
- Headquarters
- Los Angeles, United States
- Employees
- 53
- Total funding
- $5M (At-The-Market Equity Offering)
- Business model
- B2B
Immix Biopharma, Inc. pricing
Plans as published by Immix Biopharma, Inc.. Current prices on immixbio.com
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 14 Jun 2023 | At-The-Market Equity Offering | $5M |
Tech stack
Detected on immixbio.com, last scanned 29 Oct 2026. Run your own scan
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- Email provider
- Microsoft 365
Immix Biopharma, Inc. scores 37. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is Immix Biopharma, Inc. trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Immix Biopharma, Inc. is 82 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Immix Biopharma, Inc. raised?
Immix Biopharma, Inc. has raised a total of $5M in funding. The most recent round on record is At-The-Market Equity Offering.
How many employees does Immix Biopharma, Inc. have?
Immix Biopharma, Inc. has approximately 53 people on record.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for Immix Biopharma, Inc.
